NeoGenomics’ Solid Tumor Test Gets New York State Approval
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read MorePosted by Andy Lundin | Oct 22, 2024 | Lung Cancer, Molecular Diagnostics |
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read MorePosted by Andy Lundin | Oct 9, 2024 | Leukemia |
Researchers have developed a CRISPR-based diagnostic test that accurately detects gene fusions in APL and CML within two hours.
Read MorePosted by Andy Lundin | Oct 8, 2024 | Leukemia, Sequencing Systems |
The next-generation sequencing assay delivers rapid and comprehensive genetic profiling for AML patients, guiding precise treatment decisions.
Read MorePosted by Andy Lundin | Sep 23, 2024 | Flow Cytometry, Leukemia |
A new diagnostic classification module for AHEAD Medicine’s Cyto-Copilot platform enhances AML versus non-neoplastic classification.
Read MorePosted by Chris Wolski | Jul 4, 2024 | Sequencing Systems |
Whole genome sequencing has improved care for some children with cancer in England and can potentially replace multiple standard tests.
Read More